MDRX — Veradigm Cashflow Statement
0.000.00%
HealthcareAdventurousMid Cap
- $476.37m
- $230.17m
- $588.02m
Annual cashflow statement for Veradigm, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 408 | -183 | -133 | 134 | -20 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -476 | 78.1 | -10.8 | -360 | 18.1 |
Discontinued Operations | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -60.1 | -18.4 | -152 | -23.5 | 57.4 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 67.9 | 46.3 | -107 | -75.4 | 116 |
Capital Expenditures | -145 | -130 | -105 | -78.6 | -32.3 |
Purchase of Fixed Assets | |||||
Software Development Costs | |||||
Other Investing Cash Flow Items | 393 | -30.6 | 1,720 | 66.4 | 617 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 248 | -161 | 1,615 | -12.2 | 585 |
Financing Cash Flow Items | 128 | -93 | -10.4 | -16.4 | -32.1 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -293 | 67.3 | -1,110 | -259 | -445 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 22.3 | -47.3 | 400 | -347 | 256 |